A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. Ayrmid has offered to buy bluebird for $4.5-apiece upfront, plus a one-time contingent value right (CVR) of $6.84 per share tied to a sales milestone, bluebird said Friday. The upfront tag is 50% higher than the $3-per-share selling price that bluebird has previously penned with Carlyle and SK Capital Partners. That private equity duo’s buyout offer also includes a $6.84-per-share CVR. For now, bluebird’s board has not changed its mind and the company remains bound by the original merger agreement. But it’s willing to look at the new unsolicited non-binding written proposal.
Read the full article: Bluebird Bio Receives Rival M&A Bid Worth 50% Higher than Carlyle-SK Offer //
Source: https://www.fiercepharma.com/pharma/bluebird-bio-receives-rival-ma-bid-worth-50-higher-carlyle-sk-offer